(firstQuint)A Trial of X4P-001 in Patients With WHIM Syndrome.

 The primary objective of Phase 2 is to determine the safety, tolerability, and dose selection of X4P-001 for Phase 3 in patients with WHIM syndrome.

 The primary objective of Phase 3 is to demonstrate that X4P-001 is an effective treatment for patients with WHIM syndrome, as demonstrated by sustained increases in circulating neutrophils and lymphocytes that are associated with improvements in clinical manifestations of WHIM syndrome.

.

 A Trial of X4P-001 in Patients With WHIM Syndrome@highlight

The overall objective is to evaluate X4P-001 in the treatment of patients with WHIM Syndrome.

